On December 16, 2022, the Food and Drug Administration granted approval to Adstiladrin, the first gene therapy indicated for the treatment of adult patients with a specific form of unresponsive non-muscle-invasive bladder cancer (NMIBC). According to the manufacturer, Ferring, the gene therapy should be available in the second half of 2023. Although pricing information for Adstiladrin has not yet been announced, it is expected to have an estimated cost of $181,000 annually and compete with Keytruda.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-high-risk-non-muscle-invasive-bladder-cancer
